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Abstract: Measuring tumor response to chemotherapy is important 
for both clinical decision-making and for multi-institutional studies. 
Thymoma tends to spread along the pleura: a challenge for accurate 
tumor measurement. Inaccurate and inconsistent tumor measure-
ments often compromise results from clinical trials that are depen-
dent on identifying response rate and progression-free survival. In 
this article, we sought to provide a practical guide on how to mea-
sure thymoma by the International Thymic Malignancy Interest 
Group’s recommendations for standard outcome measures. The aim 
of this article is to clarify this measuring technique, lead to consis-
tency between institutions, and minimize intra- and interobserver 
variability.
Key Words: Thymic neoplasm, International Thymic Malignancy 
Interest Group, Response measurement.
(J Thorac Oncol. 2014;9: S119–S124)
Over the years, the treatment and follow-up of thymic epi-thelial tumors has been diverse and influenced by ret-
rospective single institution series. The International Thymic 
Malignancy Interest Group (ITMIG) was formed in 2010 to 
develop an infrastructure that facilitates large-scale and mean-
ingful research for this rare disease. As part of this process, 
ITMIG developed standard outcome measures and standard 
computed tomography (CT) report terms to facilitate collab-
orative, multi-institutional studies for thymic tumors.1,2 The 
following guide is being proposed to clarify ITMIG’s rec-
ommendations for measuring tumor response to nonsurgical 
therapies, and to help standardize the measurement of tumor 
burden in multi-institutional studies.
Assessment of the change in tumor burden after treat-
ment is important for several reasons. First, it is utilized clini-
cally to determine whether a given therapeutic modality (e.g., 
chemotherapy or radiation) should be continued or altered. 
Second, tumor regression is used as an endpoint in phase II 
clinical trials for assessing the antitumor effect of new thera-
peutic agents. Third, because thymic epithelial tumors are 
somewhat more indolent relative to other solid tumors, and 
patients often die from competing causes, time to progres-
sion is often used as a measure of efficacy rather than overall 
survival in clinical trials. Given the importance of assessing 
the change in tumor burden, combined with the collabora-
tive, multi-institutional nature of thymic tumor research, it has 
become essential that data involving tumor response be col-
lected in a standardized manner. Standardization implies that 
each study site assesses tumor response in a similar, reproduc-
ible manner using clear definitions (Table 1).
The recommended imaging modality for the staging 
and follow-up of thymic epithelial tumors is CT.1 Although 
magnetic resonance imaging can replace CT in the follow-
up of patients after resection of the thymoma to decrease 
cumulative radiation dose,1 when measurable disease is fol-
lowed, CT is the recommended imaging modality as it is 
the most reproducible method to measure lesions selected 
for response assessment.3 The assessment of tumor response 
during follow-up imaging is dependent on diameter mea-
surements. The development of heterogeneity in tumor den-
sity represents a potential alternative to size. Despite the 
fact that some tumors, including thymic epithelial tumors, 
may respond to therapy by undergoing necrosis resulting in 
increased heterogeneity, a reliable and reproducible method 
for measuring tumor heterogeneity has yet to be proven and 
is thus not currently recommended for tumor response mea-
surements. Similarly, although volumetric imaging analy-
sis as a measurement of tumor treatment response has been 
randomly used,4,5 questions remain as to the precision and 
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accuracy of such tumor volume measurements,6–9 software 
for such measurements is not universally available, and 
measurements of thymic tumors may be more laborious and 
time intensive as they would require manual delineation of 
tumor because these tumors often abut normal mediasti-
nal structures of similar density limiting automated tumor 
delineation. Thus, currently, volumetric assessment has not 
been universally accepted, leaving diameter measurements 
depicted on axial slices as the accepted method for follow-
ing tumor response to treatment.
Although functional imaging, particularly [18F]fluo-
rodeoxyglucose positron emission tomography imaging, has 
been utilized to evaluate tumor response in some other solid 
tumor types, the role of such imaging has yet to be defined 
in thymic epithelial tumors, in part because some histo-
logic types of thymic epithelial tumors have very low [18F]
fluorodeoxyglucose activity.10 Imaging with positron emis-
sion tomography in multi-institutional studies also suffers 
from a lack of standardization of imaging techniques and 
protocols, which may result in quantitative variability that 
confounds the assessment of tumor response to therapy.11,12 
As a result, objective tumor response in most clinical trials 
still relies on anatomical measurement of tumor size.
The use of tumor size measurements to assess response 
to therapy has evolved over the years, and has included the 
World Health Organization,13 Response Evaluation Criteria 
In Solid Tumors (RECIST)14 and RECIST version 1.13 crite-
ria. Currently, the most commonly used method is RECIST 
version 1.1, which is basically a unidimensional tumor mea-
surement (Appendix 1). It is the recommendation of ITMIG 
that RECIST version 1.1 be used for response assessment, but 
with certain caveats and modifications.1 First, because thymic 
epithelial tumors are often large, irregular in size, insinuating 
around vessels, and may have vague borders, pretreatment 
and posttreatment imaging should be interpreted by the same 
individual, ideally a radiologist experienced with tumor mea-
surements,1 to decrease interobserver variability.8,15 Second, 
because thymic tumors tend to spread along the pleura, the 
RECIST version 1.1 criteria may not be ideal. This is because 
RECIST version 1.1 limits pleural assessment to two pleural 
lesions and requires the measurement of long-axis diameters 
of pleural lesions. Long-axis measurement of pleural tumor 
deposits is not as reproducible as short-axis measurement of 
these lesions.16 As a result, ITMIG recommends adhering to 
the criteria previously established for pleural measurements 
in mesothelioma (Appendix 2) (Table 2).1,16
The purpose of this guide is to summarize the measure-
ment criteria for assessing treatment response and follow-up 
of thymic epithelial tumors, while guiding the reader through 
a true measurement of a sample tumor to serve as a standard 
for future multi-institutional trials.
METHODS
The process used in development of this article was 
designed to represent a broad consensus within the community 
of clinicians and researchers interested in thymic diseases. A 
core workgroup consisting of radiologists, surgeons, and med-
ical oncologist (Marcelo F. Benveniste, Robert J. Korst, Arun 
TablE 2.  Summary of Major Changes between RECIST 1.1,3 Modified Mesothelioma Measurement,16 and ITMIG Modified 
Criteria for Measuring Tumor Burden in Thymic Epithelial Tumors
RECIST 1.13 Modified Mesotheliomaa16 ITMIG
Overall tumor burden Five lesions (two per organ) Ten lesions (five per organb) Five lesions (two per organb)
Target lesion measurement plane Axial Axial Axial
Target lesion axis to be measured Long axis (except lymph nodes) Long axis (except pleura) Long axis (except pleura and lymph nodes)
Lymph node: measurement plane Short axis Long axis Short axis
Lymph node: minimum size to be 
included as target lesion
15 mm Not mentioned 15 mm
Pleura: measurement plane Long axis Short axis Short axis
Pleura: number of lesions allowed 2 Unidimensional measurement 
composed of six lesions: two 
sites at three different levels
Unidimensional measurement composed 
of six lesions: two sites at three different 
levels
aThe modified RECIST criteria for measuring mesothelioma introduced a new method of measuring the pleura,16 whereas the rest of target organs were based on the original 
RECIST14 that preceded RECIST 1.13 and differs from it in some respects.
bThe pleura is considered as one organ and receives a unidimensional measurement from the sum of up to six lesions.
RECIST, Response Evaluation Criteria In Solid Tumors; ITMIG, International Thymic Malignancy Interest Group.
TablE 1.   Tumor Response Definitions (Abbreviated from 
RECIST Version 1.1)3
CR, complete response; PR, partial response; PD, progressive disease; SD, stable 
disease; RECIST, Response Evaluation Criteria In Solid Tumors.
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Rajan, Frank C. Detterbeck, and Edith M. Marom) reviewed 
the existing literature and ITMIG recommendations for CT 
measurement of tumor response.1 This workgroup formu-
lated preliminary recommendations, which were refined by 
an extended workgroup (David Ball, Andrea Bezjak, Gedske 
Daugaard, Conrad Falkson, Michelle S. Ginsberg, Rohit Lal, 
Sanjay Popat, Ami N. Rubinowitz, and Heather A. Wakelee) 
and distributed to all ITMIG members for further input. The 
final recommendations, which are presented in this article, 
were approved and adopted by ITMIG members as a standard 
to use going forward.
ITMIG-Modified Criteria for Measuring 
Tumor burden in Thymic Epithelial Tumors
All measurable lesions up to a maximum of two 
lesions per organ and five lesions in total, representative of 
all involved organs, should be identified as target lesions and 
recorded and measured at baseline. The longest diameter of 
the target lesions should be measured. An exception to this 
rule is the measurement of involved pleura and lymph nodes, 
in which the short-axis diameter should be measured (Fig. 1). 
When the pleura serves as a target organ and is either diffusely 
involved or involved in multiple locations, the tumor thickness 
FIGurE 1.  Illustration of correct thymic tumor measurement and response assessment using ITMIG-modified RECIST criteria. A, 
A sketch of an axial image through the level of the main bronchi (**) demonstrates the primary thymic tumor (T). Its long-axis 
diameter measurement is illustrated. Pleural metastases (P) are also shown and their short-axis diameters are measured perpen-
dicular to the chest wall they abut. B, A sketch of an axial image through the level of the carina (C) shows an enlarged low right 
paratracheal lymph node (N). Its short-axis diameter is measured. It is important to note that using ITMIG’s recommendations 
for measuring thymic tumor burden, deposits are measured as a unidimensional measurement of the long axis of the tumor. 
An exception to this rule is the measurement of lymph nodes and pleural deposits. These are measured through their short-axis 
diameter. C, A sketch of an axial image at the same level as A which represents a sketch after therapeutic intervention. D, A sketch 
of an axial image at the same level as B which represents a sketch after therapeutic intervention. Presuming all sites of disease 
are represented in the images provided, for calculation of this patient’s response, the baseline unidimensional measurement is 
14.1 cm. This measurement is comprised of the sum of the primary tumor (8 cm), the pleural disease (4.4 cm = 2.3 + 2.1), and 
the lymph node (1.7 cm). After therapy, the unidimensional measurement has decreased to 7.6 cm, as it is comprised the sum 
of the primary tumor (4 cm), the pleural disease (2.7 cm = 1.7 + 1), and the lymph node (0.9 cm), all measured at the same level 
utilized in the pretreatment assessment of tumor burden. Because the total tumor measurement decreased by 46% after therapy, 
this example constitutes a partial response. Ao, aorta; SVC, superior vena cava; *, esophagus; LPA, left pulmonary artery; PA, main 
pulmonary artery; ITMIG, International Thymic Malignancy Interest Group; RECIST, Response Evaluation Criteria In Solid Tumors.
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perpendicular to the chest wall or mediastinum is measured in 
up to two locations at three separate levels on the CT scan.1 
The sum of these measurements (up to a maximum of six) 
defines the overall pleural measurement, which is added to the 
nonpleural target lesions up to a total of five (Fig. 2).
Measurement Tips for applying 
ITMIG-Modified rECIST Criteria
General
•  ITMIG-modified RECIST criteria apply to spiral CT 
scans with a slice thickness of up to 5 mm, though thinner 
contiguous slices such as 2.5 mm are preferable. Ideally, 
all subsequent CT scans should be performed with the 
same slice thickness for greatest accuracy.
•  Measurements are performed from the axial image.
•  To ensure accuracy, all measurements must be performed 
electronically using the same window setting on con-
secutive studies. We recommend using the “soft tissue” 
setting (not lung windows), as it enables accurate pleural 
mass measurements and mediastinal mass measurements 
with the electronic calipers and avoids the incorporation 
of chest wall or mediastinal fat within the calculations, 
which are not easily identified when using lung windows. 
An exception to this rule is the pulmonary metastasis, 
defined as a pulmonary nodule completely surrounded 
FIGurE 2.  Calculation of tumor burden using a contrast enhanced chest CT of a 68-year-old woman with newly diagnosed 
thymoma, showing the measurement of the primary tumor, lymph node, and pleural metastatic disease measured at three 
separate levels more than 1 cm apart. A, Axial image at the level of the carina (c) demonstrates a soft-tissue mass in the anterior 
mediastinum that measures 7.7 cm in long-axis diameter and represents the primary tumor. When measuring tumors that abut 
the pericardium, one should not include the pericardial fluid in such measurements (P) which can appear similar to the primary 
tumor. Incidental note is made of an enlarged low right paratracheal lymph node, with a short-axis diameter of 1.6 cm. Lymph 
nodes are measured using the short-axis diameter. Because nodal disease is rare in thymoma, if a given lymph node is used as 
a target lesion, histologic confirmation may be beneficial if it will be utilized for response assessment. B, Axial image at the level 
of the LBV demonstrates the short-axis measurement of two foci of pleural metastatic disease, 2.8 and 3.1 cm. C, Axial image 
at the level of the superior portion of the transverse aorta (Ao) demonstrates the short-axis measurement of two foci of pleural 
metastatic disease, 2.6 and 2.4 cm. D, Axial image at the level of the foramen ovale (arrow) demonstrates the short-axis mea-
surement of two foci of pleural metastatic disease, 1.9 and 2.2 cm. Note that the often noncontiguous pleural involvement in 
thymic epithelial malignancies may necessitate the selection of a measurement slice below the level of the main bronchi. When 
this occurs, one should attempt to select a reproducible anatomical landmark, in this case, the foramen ovale. The calculation 
of tumor burden in the case displayed consists of the summation of the three organs involved: the primary tumor (7.7 cm), the 
mediastinal lymph node (1.6 cm), and the unidimensional pleural measurement (15 cm = 2.8 + 3.1 + 2.6 + 2.4 + 1.9 + 2.2). 
Thus, the overall tumor burden is 24.3 cm (7.7 + 1.6 + 15). CT, computed tomography; LBV, left brachiocephalic vein.
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by lung, which should be measured using “lung window” 
settings.1,2
•  The recorded total measurement is the summation of up 
to five target lesions, which in advanced thymic tumors 
usually includes: the primary tumor, the pleural mea-
surement (composed of up to six pleural measurements 
as described below), and any additional available mea-
surable lesion such as nodal, abdominal, or pulmonary 
lesions (up to five lesions in total) (Fig. 2).
•  Image magnification may aid in measurements obtained 
using electronic calipers.
Primary thymic tumor
•  Measurable lesions must have a longest diameter of 
10 mm or greater.
•  Well-defined lesions are more accurate to measure.
•  The largest tumor diameter should be chosen.
•  Normal pericardium should not be incorporated into this 
measurement. Sometimes fluid in the pericardial recess may 
be of similar attenuation to the primary tumor (Fig. 2A).
•  Tumor lesions situated in a previously irradiated area 
should not be considered measurable unless a specific 
study protocol details the conditions under which such 
lesions may be measured.
Lymph nodes
•  Lymph nodes are considered as a separate organ to 
measure.
•  Up to two lymph nodes may be measured.
•  For unidimensional lymph node measurements, the short 
axis of the lymph node should be measured at baseline 
and at every follow-up scan (Figs. 1B and 2A).
•  To be considered as pathologically enlarged and mea-
surable at baseline, the lymph node short-axis diam-
eter should be larger than 15 mm. On follow-up scans, 
lymph node size will continue to be measured even if it 
regressed to less than 15 mm in short-axis diameter.
Pleural involvement
•  The pleural disease to be measured should have a short-
axis diameter of at least 10 mm, as lesions less than 
10 mm are considered nonmeasurable.
•  Larger lesions are easier and more accurate to measure. 
The largest or thickest region of the pleural disease should 
be chosen for measurement. Magnifying the image may 
aid in measurement.
•  It should be ensured that differentiation of normal chest 
wall from the tumor is clear at the point of measurement. 
Measuring regions where tumor infiltration obscures the 
interface of the tumor to normal tissue should be avoided. 
A good interface for measurement is usually one where 
the tumor abuts fat or an intact rib/vertebral body, as the 
density of the pleural tumor differs significantly from 
bone or fat and the difference can be easily appreciated. 
In contrast, an interface of tumor with muscle should be 
avoided, as muscle and tumor have similar CT densities 
and are often difficult to distinguish when they abut one 
another.
•  To obtain the short axis of the pleural disease, the dis-
tance between the point where the tumor abuts the chest 
or the mediastinal border and the point where the pleural 
disease touches normal lung tissue should be measured 
using electronic calipers. The shortest route possible 
is usually the one perpendicular to the chest wall/
mediastinum.
•  Three different axial slices should be chosen (Figs. 2B–D), 
obtaining two measurements per slice, thus resulting in 
six separate measurements. Although choosing pleural 
lesions above the main bronchi is more reproducible 
from one study to the other due to less pleural motion 
with differences in inspiratory effort, unlike mesotheli-
oma, with thymic tumors, the pleural spread may be non-
confluent. When the pleural metastases are nonconfluent, 
measurement of pleural deposits below the level of the 
main bronchi is allowed. As such, a level with a repro-
ducible anatomical landmark should be chosen (Fig. 2D).
Calculation of overall tumor burden and  
response to therapy
The unidimensional measurements of up to five target 
lesions on the pretreatment CT are added together to obtain 
the total tumor measurement. If pleural disease is present, the 
summation of the pleural measurements (maximum of six) 
comprises the total pleural measurement, which is then added 
to a maximum of four other unidimensional measurements of 
the primary tumor, lymph nodes, and/or any other metastatic 
disease (Fig. 2). The identical measurements are then made at 
the same levels on the posttreatment CT. The percent change 
in tumor burden between the scans is then calculated, and clas-
sified according to the criteria in Table 1.
COnCluSIOn
Ideally, the assessment of tumor response to treatment 
should be centralized in multi-institutional studies, but for 
practical reasons this is not always possible. This guide can 
be used in routine clinical practice but is particularly meant 
for standardizing thymic tumor measurements in multi-insti-
tutional studies. Such standardization will help in reducing 
errors in tumor measurement and help obtain appropriate con-
clusions in therapeutic trials in thymic tumors.
aPPEnDIX 1. Summary of Measurement of 
Treatment response using rECIST Version 1.13
To assess treatment response, it is necessary to estimate the overall 
tumor burden on a pretreatment scan, and compare this with a similar mea-
surement obtained from a posttreatment scan. When more than one measurable 
lesion is present at baseline, all lesions up to a maximum of five (maximum 
of two lesions per organ and representative of all involved organs) should be 
identified, measured, and recorded as target lesions.3 Target lesions should be 
selected on the basis of their size (larger is preferable) and measured along 
their longest diameter in the axial plane. Lymph nodes are defined as measur-
able when they exceed 15 mm in short-axis diameter using CT. A sum of the 
diameters (longest for nonnodal lesions, short axis for nodal lesions) for all 
target lesions is then calculated and recorded. The target lesions are identified 
on follow-up studies and measured at the same levels as on the baseline study. 
The sum of the diameters is then calculated and recorded in a similar manner. 
Responses are then classified as shown in Table 1.
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aPPEnDIX 2. Summary of Modified  
Measurement of Tumor burden 
for Mesothelioma16
The modified system for measuring mesothelioma is based on an ear-
lier version of RECIST14 while modifying the way the pleura is measured. The 
pleura may be used as a target organ. However, instead of measuring only up 
to two sites of involvement as suggested by RECIST14 and RECIST version 
1.1,3 unidimensional measurements of pleural tumor thickness perpendicular 
to the chest wall or mediastinum should be performed. These measurements 
are obtained from two sites at three different levels on CT scan. The levels 
used for measurement must be at least 1 cm apart, and related to anatomical 
landmarks in the thorax, preferably above the level of division of the main 
bronchi. On follow-up imaging after therapy, pleural thickness must be mea-
sured at the same position and level. Nodal, subcutaneous, and other lesions 
are measured unidimensionally as per the RECIST criteria.14 Unidimensional 
measurements are added together to produce the total tumor measurement.
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